Nach Herzkatheter und Stent-Implantation kann die Rezeptur zweier Thrombozyenfunktionshemmer auf drei Monate begrenzt werden, sofern der Patient keinen ST-Hebungsinfarkt hat.
This is a preview of subscription content, log in via an institution to check access.
Quellen
Jang Y, et al.; Ticagrelor With Or Without Aspirin In Acute Coronary Syndrome After Percutaneous Coronary Intervention: Randomized Evaluation Of Ticagrelor Monotherapy After 3-month Dual-antiplatelet Therapy In Acute Coronary Syndrome
Angiolillo D, et al.; Ticagrelor With And Without Aspirin In High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: Insights From The TWILIGHT Trial
Dangas G, et al.; Safety And Efficacy Of Ticagrelor Monotherapy After Complex PCI: The TWILIGHTCOMPLEX Substudy Die drei Studien wurden vorgestellt in der Sitzung „Late-Breaking Clinical Trials 4“ beim digital präsentierten Kongress des American College of Cardiology (ACC) 2020 (ACC2020/WCC Virtual Experience)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Einecke, D. Duale Plättchenhemmung nur drei Monate notwendig. MMW - Fortschritte der Medizin 162, 13–14 (2020). https://doi.org/10.1007/s15006-020-0368-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-020-0368-0